🟢 First Tracks Biotherapeutics is trading 6.9% up today after Guggenheim initiated coverage with a Buy rating

First Tracks Biotherapeutics is trading 6.9% up at $41.17 after Guggenheim initiated coverage with a Buy rating and a $100 price target on September 16, 2026.

• UBS also reportedly began coverage with a Buy rating, strengthening institutional interest.
• The rally is additionally supported by expected fourth-quarter 2026 ANB033 Phase 1b data and a positive biotech-sector backdrop.
• The broader market is firmly higher, supporting risk appetite, while analyst actions remain the clearest company-specific catalyst.